Rivaroxaban for treatment of HIT: a riveting first experience

Thromb Res. 2015 Jan;135(1):1-2. doi: 10.1016/j.thromres.2014.10.019. Epub 2014 Nov 1.

Authors

Lori-Ann Linkins¹, Theodore E Warkentin²

Affiliations

¹ Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: linkinla@mcmaster.ca.
² Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: twarken@mcmaster.ca.

PMID: 25466840
DOI: 10.1016/j.thromres.2014.10.019

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Factor Xa Inhibitors / therapeutic use*
Female
Heparin / adverse effects*
Heparin Antagonists / therapeutic use*
Humans
Male
Morpholines / therapeutic use*
Rivaroxaban
Thiophenes / therapeutic use*
Thrombocytopenia / drug therapy*

Substances

Factor Xa Inhibitors
Heparin Antagonists
Morpholines
Thiophenes
Heparin
Rivaroxaban